Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Colorectal Adenocarcinoma: early-phase trial registry
7 of 15 indexed Metastatic Colorectal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Metastatic Colorectal Adenocarcinoma: 15 US clinical trials tracked, 7 recruiting.
Metastatic Colorectal Adenocarcinoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-colorectal-adenocarcinoma
OPEN 7 | RECR 47% | LATE 2 | EARLY 13 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Autism (47% recruiting · 105 trials)
Metastatic Colorectal Adenocarcinoma lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Colorectal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Colorectal Adenocarcinoma recruits in line with its size-band peers.
7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Colorectal Adenocarcinoma research.
M.D. Anderson Cancer Center accounts for 3 of 15 trials (20%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Colorectal Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 15 trials that report a genuine target (sentinel values excluded). 10 of those (66.7%) plan for fewer than 100 participants.
-
Metastatic Colorectal Adenocarcinoma research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Alliance for Clinical Trials in Oncology
NCT05673148
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
NCT07318805
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
NCT07130903
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
NCT04511039
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
NCT06102902
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT06696768
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
University of Southern California
NCT06336902
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
NCT02997228
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
NCT02600949
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
NCT03087071
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
NCT05672316
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
NCT04117945
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
NCT05627635
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
NCT04729322
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT02023333
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Colorectal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Colorectal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Colorectal Adenocarcinoma page
15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Metastatic Colorectal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Colorectal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Colorectal Adenocarcinoma condition card totals 15 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.